A Case of Recurrent Acute Pancreatitis Following Ocrelizumab Use
April 2024
in “
DAHUDER Medical journal
”
Studysummary This case report presents an instance of acute pancreatitis following the use of ocrelizumab and suggests that its B lymphocyte suppression may contribute to pancreatitis by affecting cytokine release and T lymphocyte regulation. Our plain-language summary of this paper — not a Tressless recommendation.
The document presents a case of acute pancreatitis following the use of ocrelizumab, a monoclonal antibody that suppresses peripheral B lymphocytes by targeting CD20 receptors. Drugs are a relatively rare cause of acute pancreatitis, with an incidence of 0.1-2%. The case suggests that the suppression of B lymphocytes by ocrelizumab may induce the release of proinflammatory cytokines and disrupt T lymphocyte regulation, potentially causing pancreatitis. Therefore, ocrelizumab should be considered as a possible cause of pancreatitis in patients receiving this treatment.
